GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Capex-to-Operating-Income

DuoGenic StemCells (ROCO:7607) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

DuoGenic StemCells's Capital Expenditure for the six months ended in Jun. 2024 was NT$-0.11 Mil. Its Operating Income for the six months ended in Jun. 2024 was NT$-32.75 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

DuoGenic StemCells Capex-to-Operating-Income Historical Data

The historical data trend for DuoGenic StemCells's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Capex-to-Operating-Income Chart

DuoGenic StemCells Annual Data
Trend Dec21 Dec22 Dec23
Capex-to-Operating-Income
- - -

DuoGenic StemCells Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial - - - - -

Competitive Comparison of DuoGenic StemCells's Capex-to-Operating-Income

For the Biotechnology subindustry, DuoGenic StemCells's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Capex-to-Operating-Income falls into.


DuoGenic StemCells Capex-to-Operating-Income Calculation

DuoGenic StemCells's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.001) / -44.885
=N/A

DuoGenic StemCells's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.114) / -32.745
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DuoGenic StemCells  (ROCO:7607) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

DuoGenic StemCells Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Capex-to-Operating-Income
Comparable Companies
Traded in Other Exchanges
N/A
Address
Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN
Website
https://www.dgsc.com.tw
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines